Cookie Consent by Free Privacy Policy website Ypsomed teams up with Philips for the development of its new digital services to simplify medication adherence monitoring
ottobre 04, 2018 - Philips

Ypsomed teams up with Philips for the development of its new digital services to simplify medication adherence monitoring

Comunicato Stampa disponibile solo in lingua originale. 

Press release available only in original language. 

  • The two companies agree to build a solution for Ypsomed’s new SmartServices™ based on #philips #healthsuite digital platform
  • The combination of #ypsomed connected self-medication devices with Philips’ #healthsuite digital platform will allow Ypsomed’s pharmaceutical customers to deliver value-added services for enhanced patient outcomes

Burgdorf, Switzerland and Eindhoven, the Netherlands – Ypsomed, a leading developer and manufacturer of injection and infusion systems for self-medication, and Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a collaboration to jointly develop and deploy new digital self-medication adherence monitoring services based on Ypsomed’s connected devices and Philips’ cloud-based #healthsuite digital platform. To this end, the companies have signed a memorandum of understanding and aim to sign the definitive agreements in the fourth quarter of 2018. 

With the new SmartServices™, #ypsomed aims to extend its medical device business, by providing a new turnkey digital solution for medication adherence monitoring and smart device management to its pharmaceutical customers. Ypsomed’s SmartServices™ will be enabled by Philips’ #healthsuite digital platform, a cloud-based platform which was purpose-built for the complex challenges in healthcare, and provides tools and services focused on ease-of-integration, digital lifecycle management, and end-to-end security. The new digital services aim to address a wide range of device-oriented challenges and support self-medication services for patients across chronic disease states, such as diabetes, multiple sclerosis and rheumatoid arthritis.

Further information in the press release to download